Back to Stocks

SLN

Silence Therapeutics plc
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Silence Therapeutics is demonstrating a strategic shift toward capital efficiency, reporting a substantial 47% reduction in net losses for the first quarter of 2026.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the reduction in nominal losses, Silence Therapeutics remains a high-burn entity with a precarious revenue model.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every SLN filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a critical inflection point, balancing aggressive cost-cutting against a ticking clock of clinical milestones. The dramatic reduction in R&D spend suggests a transition from a broad discovery phase to a focused execution phase, but the lack of organic revenue leaves the firm exposed to binary clinical outcomes. The shift in functional currency to USD further reflects a move toward stabilizing its financial reporting for a global investor base. Ultimately, the investment case hinges on whether the 'lean biotech' transformation can bridge the gap to the 2028 runway. The regain of SLN312 rights and the upcoming Phase 2 data for Divesiran represent the primary levers for value creation. Investors must weigh the ability of management to secure a new partner for Zerlasiran against the systemic risk of a cash-burn rate that still far exceeds current income.

Selected Quarter

Core Takeaway

Silence is aggressively cutting costs to extend its runway into 2028, shifting from a high-spend R&D phase to a catalyst-driven valuation play.

Investor Lens

The trade-off is between the ability to cut costs and the inability to generate meaningful revenue without a major new partnership.

Watch Next

Topline Phase 2 results for Divesiran anticipated in Q3 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.03Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Net loss reduced by 47% due to significant R&D cost cutting.

margin expansion
70%
neutralMay 7

Regained full rights to SLN312 following AstraZeneca's exit from the program.

divestiture
50%
bearishMay 7

Continued operating losses with negligible revenue of $0.4M.

earnings miss
60%
bullishMay 7

Net loss reduced by 47% due to significant R&D cost cutting.

margin expansion
70%
neutralMay 7

Regained full rights to SLN312 following AstraZeneca's exit from the program.

divestiture
50%
bearishMay 7

Continued operating losses with negligible revenue of $0.4M.

earnings miss
60%
bullishMay 7

Net loss reduced by 47% due to significant R&D cost cutting.

margin expansion
70%
neutralMay 7

Regained full rights to SLN312 following AstraZeneca's exit from the program.

divestiture
50%
bearishMay 7

Continued operating losses with negligible revenue of $0.4M.

earnings miss
60%
bullishMay 7

Net loss reduced by 47% due to significant R&D cost cutting.

margin expansion
70%
neutralMay 7

Regained full rights to SLN312 following AstraZeneca's exit from the program.

divestiture
50%
bearishMay 7

Continued operating losses with negligible revenue of $0.4M.

earnings miss
60%
bullishMay 7

Net loss reduced by 47% due to significant R&D cost cutting.

margin expansion
70%
neutralMay 7

Regained full rights to SLN312 following AstraZeneca's exit from the program.

divestiture
50%
bearishMay 7

Continued operating losses with negligible revenue of $0.4M.

earnings miss
60%
bullishMay 7

Net loss reduced by 47% due to significant R&D cost cutting.

margin expansion
70%
neutralMay 7

Regained full rights to SLN312 following AstraZeneca's exit from the program.

divestiture
50%
bearishMay 7

Continued operating losses with negligible revenue of $0.4M.

earnings miss
60%
bullishMay 7

Net loss reduced by 47% due to significant R&D cost cutting.

margin expansion
70%
neutralMay 7

Regained full rights to SLN312 following AstraZeneca's exit from the program.

divestiture
50%
bearishMay 7

Continued operating losses with negligible revenue of $0.4M.

earnings miss
60%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a critical inflection point, balancing aggressive cost-cutting against a ticking clock of clinical milestones. The dramatic reduction in R&D spend suggests a transition from a broad discovery phase to a focused execution phase, but the lack of organic revenue leaves the firm exposed to binary clinical outcomes. The shift in functional currency to USD further reflects a move toward stabilizing its financial reporting for a global investor base. Ultimately, the investment case hinges on whether the 'lean biotech' transformation can bridge the gap to the 2028 runway. The regain of SLN312 rights and the upcoming Phase 2 data for Divesiran represent the primary levers for value creation. Investors must weigh the ability of management to secure a new partner for Zerlasiran against the systemic risk of a cash-burn rate that still far exceeds current income.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.